More on ATAI
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.54 |
|
|||
| Open | $3.45 | ||||
| 52 Wk High | $7.32 | ||||
| 52 Wk Low | $3.30 | ||||
| Day High | $3.58 | ||||
| Day Low | $3.37 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 7,352,133 | ||||
- Jefferies Reiterates Buy Rating on atai Life Sciences N.V (ATAI): "keen on ATAI's robust BPL-003 Phase IIb TRD results"
- AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
- AtaiBeckley receives FDA support for BPL-003 Phase 3 depression program
- AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
- Form 144 Atai Beckley N.V. Filed by: Feilding-Mellen Cosmo
- AtaiBeckley reports positive trial results for social anxiety drug
- AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder
- AtaiBeckley To Host Virtual Investor Day on March 6, 2026
- AtaiBeckley names Michael Faerm as chief financial officer
- AtaiBeckley Appoints Michael Faerm as Chief Financial Officer
Entities mentioned with ATAI
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- IPO | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Cowen & Co | View Related Stories »
- Show More...
